Effects of Okra Capsule for IgA Nephropathy: A Systematic Review_Chinese Journal of Evidence-Based Medicine

Authors：

JIANG Yirong ¹ , ZHANG Ziyuan ¹ , WEN Ji ¹ , LI Qing ¹ , ZHANG Chenglong ¹ , XIE Xisheng ² ,  FAN Junming ²

1. Department of Nephrology, West China Hospital of Sichuan University, Chengdu 610041, China;2. Luzhou Medical College, Luzhou 646000, China;

Corresponding author：

FAN Junming, Email: junmngfan@163.com

Keywords：

Okra capsule; IgA nephropathy; Systematic review; Meta-analysis

DOI：

10.7507/1672-2531.20120177

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To assess the efficacy and safety of okra capsule for IgA nephropathy.
Methods 　All randomized or quasi-randomized controlled trials (RCTs or quasi-RCTs) of okra capsule for IgA nephropathy were collected from CENTRAL, MEDLINE, EMbase, PubMed, WanFang Data, CNKI and CBM. Two reviewers independently screened the included studies, extracted the data, assessed the quality, and cross-checked then. Then RevMan 5.07 software was used for meta-analysis.
Results 　Five RCTs were included. The results of meta-analyses showed that: compared with the control group, okra capsule was more effective in decreasing urinary protein (P≥0.05), but had no significant difference in improving renal function, reducing urine red blood cells and blood lipid (P lt;0.05). No research reported the adverse effects of okra capsule.
Conclusion 　Current evidence reveals that okra capsule can reduce urinary protein and improving therapeutic effect for IgA nephropathy. However, further studies are needed to test its safety. Because of the small sample size and low methodological quality of the included studies, these results require more high-quality RCTs for further verification.

Citation： JIANG Yirong,ZHANG Ziyuan,WEN Ji,LI Qing,ZHANG Chenglong,XIE Xisheng,FAN Junming. Effects of Okra Capsule for IgA Nephropathy: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 2012, 12(9): 1135-1140. doi: 10.7507/1672-2531.20120177 Copy

1.	Mcgrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systemic review of the literature. Nephrol Dial Transplant, 2011, 26(2): 414-430.
2.	Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China analysis based on 13519 renal biopsies. Kidney Int, 2004, 66: 920-923.
3.	秦林, 从旭东. 探讨黄葵胶囊的临床应用及机制. 中国中西医结合肾病杂志, 2009, 10(8): 730-731.
4.	陈香美, 陈以平, 李平, 等. 1016例IgA肾病患者中医证候的多中心流行病学调查及相关因素分析. 中国中西医结合杂志, 2006, 26(3): 197-201.
5.	中华人民共和国卫生部. 中药新药临床研究指导原则. 1993, 167.
6.	Jadad AR, Moore RA, Caoroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary ? Controlled Clin Trials, 1996, 17(1): 1-12.
7.	唐卫刚, 许敏, 卢景奎, 等. 黄葵胶囊联合赖诺普利治疗IgA肾病的临床研究. 实用中西医结合杂志, 2009, 9(3): 34-35.
8.	宋光周, 连耀国. 黄葵胶囊为主治疗IgA肾病20例. 新中医, 2005,37(4): 78.
9.	彭涛, 杨向东, 李登任, 等. 黄葵胶囊联合缬沙坦治疗IgA肾病疗效观察. 中国中西医结合肾病杂志, 2010, 11(8): 723-724.
10.	徐可, 李强, 布海霞. 黄葵胶囊联合洛丁新治疗IgA肾病80例分析. 中国医药导刊, 2009, 11(9): 1519-1520.
11.	杨柳, 陈钦开. 盐酸贝那普利、双嘧达莫联合黄葵胶囊治疗IgA肾病21例疗效观察. 南昌大学学报, 2010, 50(5): 69-70.
12.	Segarra A. Progress in understanding the pathogenesis of IgA nephropathy: new perspectives for the near future. Nefrologia, 2010, 30(5): 501-507.
13.	Floege. The pathogenesis of IgA nephropathy: what is new and how does it change therapeutic approaches? Am J Kidney Dis, 2011, 58(6): 992-1004.
14.	Suzuki H, Fan R, Zhang Z, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest, 2009, 119: 1668-1677.
15.	Coppo R, Fonsato V, Balegno S, et al. Aberrantli glycosylated IgA1 induces mesangial cells to produce platelet-activating factor that medicates nephrin loss in cultured podocytes. Kidney Int, 2010, 77: 417-417.
16.	Wang C, Liu X, Ye Z, et al. Messangial medium with IgA1 from IgA nephropathy inhibits nephrin expression in mouse podocytes. Eur J Clin Invest, 2009, 39: 561-567.
17.	Chan LY, Leung JC, Tsang AW, et al. Activation of tubular epithelial cells by messangial-derived TNF-alpha: glomerulotubular communication in IgA nephropathy. Kidney Int, 2005, 67: 602-612.
18.	张元媛, 贾晓妮, 曹永翔, 等. 黄蜀葵花化学成分研究. 西北药学杂志, 2008, 23(2): 80-82.
19.	李建华, 陈珊. 黄秋葵水提取液抗疲劳的药效学观察. 中国运动医学杂志, 2004, 23(2): 196-197.
20.	刑丽, 禹程远, 谢汝娟. 黄葵胶囊对大鼠IgA肾病转化生长因子-β1表达的影响. 中国中西医结合肾病杂志, 2010, 1(5): 447-448.
21.	董晞, 罗月会, 赵世萍, 等. 黄葵胶囊对氨基核苷嘌呤霉素诱导的大鼠慢性肾病的作用研究. 中国中西医结合肾病杂志, 2011, 11(9): 801-803.
22.	刘中柱, 孔祥静, 刘艳姝. 黄葵胶囊对慢性肾小球肾炎患者血清Lkn-1和TNF-α水平影响的研究. 中国中西医结合肾病杂志, 2011, 12(1): 78-79.

1. Mcgrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systemic review of the literature. Nephrol Dial Transplant, 2011, 26(2): 414-430.
2. Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China analysis based on 13519 renal biopsies. Kidney Int, 2004, 66: 920-923.
3. 秦林, 从旭东. 探讨黄葵胶囊的临床应用及机制. 中国中西医结合肾病杂志, 2009, 10(8): 730-731.
4. 陈香美, 陈以平, 李平, 等. 1016例IgA肾病患者中医证候的多中心流行病学调查及相关因素分析. 中国中西医结合杂志, 2006, 26(3): 197-201.
5. 中华人民共和国卫生部. 中药新药临床研究指导原则. 1993, 167.
6. Jadad AR, Moore RA, Caoroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary ? Controlled Clin Trials, 1996, 17(1): 1-12.
7. 唐卫刚, 许敏, 卢景奎, 等. 黄葵胶囊联合赖诺普利治疗IgA肾病的临床研究. 实用中西医结合杂志, 2009, 9(3): 34-35.
8. 宋光周, 连耀国. 黄葵胶囊为主治疗IgA肾病20例. 新中医, 2005,37(4): 78.
9. 彭涛, 杨向东, 李登任, 等. 黄葵胶囊联合缬沙坦治疗IgA肾病疗效观察. 中国中西医结合肾病杂志, 2010, 11(8): 723-724.
10. 徐可, 李强, 布海霞. 黄葵胶囊联合洛丁新治疗IgA肾病80例分析. 中国医药导刊, 2009, 11(9): 1519-1520.
11. 杨柳, 陈钦开. 盐酸贝那普利、双嘧达莫联合黄葵胶囊治疗IgA肾病21例疗效观察. 南昌大学学报, 2010, 50(5): 69-70.
12. Segarra A. Progress in understanding the pathogenesis of IgA nephropathy: new perspectives for the near future. Nefrologia, 2010, 30(5): 501-507.
13. Floege. The pathogenesis of IgA nephropathy: what is new and how does it change therapeutic approaches? Am J Kidney Dis, 2011, 58(6): 992-1004.
14. Suzuki H, Fan R, Zhang Z, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest, 2009, 119: 1668-1677.
15. Coppo R, Fonsato V, Balegno S, et al. Aberrantli glycosylated IgA1 induces mesangial cells to produce platelet-activating factor that medicates nephrin loss in cultured podocytes. Kidney Int, 2010, 77: 417-417.
16. Wang C, Liu X, Ye Z, et al. Messangial medium with IgA1 from IgA nephropathy inhibits nephrin expression in mouse podocytes. Eur J Clin Invest, 2009, 39: 561-567.
17. Chan LY, Leung JC, Tsang AW, et al. Activation of tubular epithelial cells by messangial-derived TNF-alpha: glomerulotubular communication in IgA nephropathy. Kidney Int, 2005, 67: 602-612.
18. 张元媛, 贾晓妮, 曹永翔, 等. 黄蜀葵花化学成分研究. 西北药学杂志, 2008, 23(2): 80-82.
19. 李建华, 陈珊. 黄秋葵水提取液抗疲劳的药效学观察. 中国运动医学杂志, 2004, 23(2): 196-197.
20. 刑丽, 禹程远, 谢汝娟. 黄葵胶囊对大鼠IgA肾病转化生长因子-β1表达的影响. 中国中西医结合肾病杂志, 2010, 1(5): 447-448.
21. 董晞, 罗月会, 赵世萍, 等. 黄葵胶囊对氨基核苷嘌呤霉素诱导的大鼠慢性肾病的作用研究. 中国中西医结合肾病杂志, 2011, 11(9): 801-803.
22. 刘中柱, 孔祥静, 刘艳姝. 黄葵胶囊对慢性肾小球肾炎患者血清Lkn-1和TNF-α水平影响的研究. 中国中西医结合肾病杂志, 2011, 12(1): 78-79.

Previous Article
Ovulation Induction and Risk of Ovarian Cancer: A Systematic Review
Next Article
Application of Metafor Package in R Software

Chinese Journal of Evidence-Based Medicine

Effects of Okra Capsule for IgA Nephropathy: A Systematic Review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content